Reflections on COPD comorbidities

The progressive decline in lung function characteristic of COPD significantly impacts the quality of life and employability of affected individuals, resulting in a substantial direct and indirect socioeconomic burden. [3] It is important to note that international guidelines for COPD management often focus on isolated lung impairment rather than considering comorbidities systematically during diagnosis and treatment decisions. [...]there is a clear need for a specific system to address the management of COPD comorbidities. Furthermore, chemokine (C-X-C motif) ligand 10 (CXCL10) has emerged as a leading biomarker for detecting virally induced ECOPDs, and granulocyte colony-stimulating factor (G-CSF) has implicated in the pathogenesis of COPD and its comorbidities. [...]our previous research has identified several hemogram indexes, including the platelet–lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), the body mass index, airflow obstruction, dyspnea, and exacerbations index (BODEx) as being associated with ECOPD. [4] The concept of “IoT medicine” coined by Prof. Chunxue Bai of Zhongshan Hospital, Fudan University in China, refers to the extend the Internet’s data transfer capabilities to physical objects through various wireless devices.